Contact this trialFirst, we need to learn more about you.
Enzyme Inhibitor
Ibrutinib + Ixazomib for Waldenstrom's Macroglobulinemia
Recruiting3 awardsPhase 2
Jacksonville, Florida
This trial looks at the side effects of two drugs, ibrutinib and ixazomib, when given together to treat Waldenstrom macroglobulinemia. Enzyme inhibitors, such as ibrutinib and ixazomib, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service